Home News In print this week

Pharma developer iX Biopharma banks on online supplement sales for growth, profits

Michelle Teo
Michelle Teo12/18/2017 08:00 AM GMT+08  • 8 min read
Pharma developer iX Biopharma banks on online supplement sales for growth, profits
SINGAPORE (Dec 18): Catalist-listed iX Biopharma has launched a line of nutraceuticals that could help it turn a profit sooner than it could have done through the development of its pain management, erectile dysfunction and opioid treatment drugs. The pro
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (Dec 18): Catalist-listed iX Biopharma has launched a line of nutraceuticals that could help it turn a profit sooner than it could have done through the development of its pain management, erectile dysfunction and opioid treatment drugs. The products could also improve market sentiment toward its stock price, which hit an all-time low of 18.4 cents two months ago and is more than 50% off its IPO price two years ago.

Nutraceuticals — the compound term describing dietary supplements and fortified food products — are a fast-growing market estimated to hit US$285 billion ($384 billion) globally by 2021, growing 7.5% annually from 2016. Meanwhile, iX Biopharma has spent the last few years developing a non-opioid painkiller and patenting a sublingual wafer drug delivery system, WaferiX, which promises optimal delivery of drugs into the bloodstream and therefore a faster effect. The company’s key product, Wafermine, or ketamine in a sublingual wafer formulation, has the potential to be a star, in the face of a major backlash against opioids, particularly in the US.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.